Innate Financial Statements From 2010 to 2024
| IPH Stock | EUR 1.42 0.02 1.39% |
Check Innate Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Innate financial statements analysis is a perfect complement when working with Innate Pharma Valuation or Volatility modules.
Innate |
Innate Pharma Company Profit Margin Analysis
Innate Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Innate Pharma Profit Margin | (0.40) % |
Most of Innate Pharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innate Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Innate Pharma has a Profit Margin of -0.3999%. This is 96.43% lower than that of the Biotechnology sector and 98.26% lower than that of the Health Care industry. The profit margin for all France stocks is 68.51% lower than that of the firm.
Innate Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innate Pharma's current stock value. Our valuation model uses many indicators to compare Innate Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innate Pharma competition to find correlations between indicators driving Innate Pharma's intrinsic value. More Info.Innate Pharma is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Innate Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Innate Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Innate Pharma Financial Statements
Innate Pharma stakeholders use historical fundamental indicators, such as Innate Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Innate Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Innate Pharma's assets and liabilities are reflected in the revenues and expenses on Innate Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Innate Pharma. Please read more on our technical analysis and fundamental analysis pages.
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company was founded in 1999 and is based in Marseille, France. INNATE PHARMA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 191 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out the analysis of Innate Pharma Correlation against competitors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..